Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

doi:10.1016/S1470-2045(12)70269-3

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

The Lancet. Oncology - 1 Aug 2012

Falchook Gerald S, Lewis Karl D, Infante Jeffrey R, Gordon Michael S, Vogelzang Nicholas J, DeMarini Douglas J, Sun Peng, Moy Christopher, Szabo Stephen A, Roadcap Lori T, Peddareddigari Vijay G R, Lebowitz Peter F, Le Ngocdiep T, Burris Howard A, Messersmith Wells A, O'Dwyer Peter J, Kim Kevin B, Flaherty Keith, Bendell Johanna C, Gonzalez Rene, Kurzrock Razelle, Fecher Leslie A

Abstract excerpt

BACKGROUND: MEK is a member of the MAPK signalling cascade that is commonly activated in melanoma. Direct inhibition of MEK blocks cell proliferation and induces apoptosis. We aimed to analyse safety, efficacy, and genotyping data for the oral, small-molecule MEK inhibitor trametinib in patients with melanoma. METHODS: We undertook a multicentre, phase 1 three-part study (dose escalation, cohort expansion, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to MAP Kinase Kinase 1

Share to MAP Kinase Kinase 2

Share to Pyridones

Share to Pyrimidinones

Share to Uveal Melanoma

Share to Uveal Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 22805292
DOI: 10.1016/S1470-2045(12)70269-3
PMCID: PMC4109286

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.PMID 22805292Read ↗

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.Semantic proximity Read ↗

Trametinib in the treatment of melanoma.Semantic proximity Read ↗

Improved survival with MEK inhibition in BRAF-mutated melanoma.Semantic proximity Read ↗

BRAF and MEK gene rearrangements in melanoma: implications for targeted therapy.Semantic proximity Read ↗

Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.Semantic proximity Read ↗

BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma.Semantic proximity Read ↗

Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations.Semantic proximity Read ↗

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.Semantic proximity Read ↗

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.Semantic proximity Read ↗

Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study.Semantic proximity Read ↗

Phase II Clinical Trial of Trametinib and Low-Dose Dabrafenib in Advanced, Previously Treated BRAFV600/NRASQ61 Wild-Type Melanoma (TraMel-WT)Semantic proximity Read ↗

Update on the targeted therapy of melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.